Stock events for RenovoRx, Inc. (RNXT)
RenovoRx's stock price has experienced some fluctuations in the past six months. As of February 20, 2026, the share price was $0.91. Over the past year, the stock price has ranged between $0.70 and $1.45. On March 2, 2026, the stock price moved up by over 5.32%. RenovoRx reported second-quarter 2025 revenue of over $400,000 from RenovoCath sales, surpassing analyst consensus estimates by 28.0%.
Demand Seasonality affecting RenovoRx, Inc.’s stock price
There is no explicit information indicating demand seasonality for RenovoRx, Inc.'s products and services. The information suggests a consistent and growing clinical demand for the RenovoCath device and its TAMP therapy platform.
Overview of RenovoRx, Inc.’s business
RenovoRx, Inc. is a clinical-stage biopharmaceutical and medical technology company focused on developing innovative targeted oncology therapies. Their core offering is the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, designed for targeted therapeutic delivery. The company's major product is RenovoCath®, an FDA-cleared local drug-delivery device, which is being commercialized as a standalone product. RenovoRx is also evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in a Phase III clinical trial for locally advanced pancreatic cancer.
RNXT’s Geographic footprint
RenovoRx, Inc. is headquartered in Mountain View, California, United States. The company's commercialization efforts are primarily focused within the United States, targeting specialized oncology treatment settings. RenovoRx has been expanding its commercial footprint, with increasing numbers of U.S. cancer centers utilizing the RenovoCath device.
RNXT Corporate Image Assessment
RenovoRx has demonstrated positive developments that contribute to its brand reputation. There is increasing clinical adoption and commercial momentum for its FDA-cleared RenovoCath device. The DMC recommended continuing the Phase III TIGeR-PaC trial after reviewing interim data. The company also announced new clinical data supporting its TAMP™ therapy platform. RenovoRx is viewed as having high growth potential.
Ownership
RenovoRx, Inc.'s ownership structure includes a mix of institutional, retail, and individual investors. Institutional investors hold approximately 10.92% to 19.73% of the company's stock, while insiders own about 3.54%. Public companies and individual investors hold a significant portion, around 66.21% to 76.73% of the shares. Major institutional owners and shareholders include AIGH Capital Management LLC, Vanguard Group Inc., and others.
